Potent tumor targeting drug release system comprising MMP-2 specific peptide fragment with self-assembling characteristics

References

• Hagedorn HG Bachmeier BE Nerlich AG Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Review) Int J Oncol 2001 18 4 669 681 11251160
   PubMed Web of Science ®Google Scholar
• Mendes O Kim HT Lungu G Stoica G MMP-2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2 Clin Exp Metastasis 2007 24 5 341 351 17505812
   PubMed Web of Science ®Google Scholar
• Kondratiev S Gnepp DR Yakirevich E Expression and prognostic role of MMP-2, MMP-9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas Hum Pathol 2008 39 3 337 343 18045645
   PubMed Web of Science ®Google Scholar
• Zheng SQ Huang RQ Zhang YJ Role of matrix metalloproteinase (MMP)-2 and -9 and vascular endothelial growth factor C in lymph node metastasis of breast cancer Zhonghua Bing Li Xue Za Zhi 2010 39 4 240 244 Chinese 20654122
   PubMedGoogle Scholar
• Negro A Onisto M Pellati D Garbisa S CNTF up-regulation of TIMP-2 in neuroblastoma cells Brain Res Mol Brain Res 1997 48 1 30 36 9379846
   PubMedGoogle Scholar
• Nielsen BS Sehested M Kjeldsen L Borregaard N Rygaard J Danø K Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer Lab Invest 1997 77 4 345 355 9354769
   PubMed Web of Science ®Google Scholar
• Nguyen M Arkell J Jackson CJ Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles J Biol Chem 1998 273 9 5400 5404 9479001
   PubMed Web of Science ®Google Scholar
• Koivunen E Arap W Valtanen H Tumor targeting with a selective gelatinase inhibitor Nat Biotechnol 1999 17 8 768 774 10429241
   PubMed Web of Science ®Google Scholar
• Droppelmann CA Gutiérrez J Vial C Brandan E Matrix metalloproteinase-2-deficient fibroblasts exhibit an alteration in the fibrotic response to connective tissue growth factor/CCN2 because of an increase in the levels of endogenous fibronectin J Biol Chem 2009 284 20 13551 13561 19276073
   PubMed Web of Science ®Google Scholar
• Grant DS Kinsella JL Fridman R Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo J Cell Physiol 1992 153 3 614 625 1280280
   PubMed Web of Science ®Google Scholar
• Andey T Patel A Jackson T Safe S Singh M 1,1-Bis (3′-indolyl)-1-(p-substitutedphenyl)methane compounds inhibit lung cancer cell and tumor growth in a metastasis model Eur J Pharm Sci 2013 50 2 227 241 23892137
   PubMed Web of Science ®Google Scholar
• Hu J Chen C Su Y DU J Qian X Jin Y Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells Exp Ther Med 2012 4 6 1045 1050 23226772
   PubMed Web of Science ®Google Scholar
• Peng CW Liu XL Liu X Li Y Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significance J Transl Med 2010 15 8 101 107 20950454
   PubMed Web of Science ®Google Scholar
• Raghuwanshi SK Smith N Rivers EJ G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasis J Immunol 2013 190 10 5329 5336 23589623
   PubMed Web of Science ®Google Scholar
• Shukla S MacLennan GT Fu P Gupta S Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model Pharm Res 2012 29 6 1506 1517 22139534
   PubMed Web of Science ®Google Scholar
• Grams F Reinemer P Powers JC X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design Eur J Biochem 1995 228 3 830 841 7737183
   PubMedGoogle Scholar
• Kruse MN Becker C Lottaz D Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors Biochem J 2004 378 Pt 2 383 389 14594449
   PubMed Web of Science ®Google Scholar
• Chu QS Forouzesh B Syed S A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas Invest New Drugs 2007 25 4 359 367 17237909
   PubMedGoogle Scholar
• Brinker BT Krown SE Lee JY Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium Cancer 2008 112 1083 1088 18224669
   PubMed Web of Science ®Google Scholar
• Orchard J Massey A Brown R Cardon-Dunbar A Hofmann J Successful management of tendinopathy with injections of the MMP-inhibitor aprotinin Clin Orthop Relat Res 2008 466 7 1625 1632 18449616
   PubMed Web of Science ®Google Scholar
• Gapski R Hasturk H Van Dyke TE Systemic MMP inhibition for periodontal wound repair: results of a multi-centre randomized-controlled clinical trial J Clin Periodontol 2009 36 2 149 156 19207891
   PubMed Web of Science ®Google Scholar
• Skulason S Holbrook WP Kristmundsdottir T Clinical assessment of the effect of a matrix metalloproteinase inhibitor on aphthous ulcers Acta Odontol Scand 2009 67 1 25 29 18991147
   PubMed Web of Science ®Google Scholar
• Shi NQ Gao W Xiang B Qi XR Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage Int J Nanomedicine 2012 7 1613 1621 22619516
   PubMed Web of Science ®Google Scholar
• Bae M Cho S Song J Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis Drugs Exp Clin Res 2003 29 1 15 23 12866360
   PubMedGoogle Scholar
• Lee GY Park K Kim SY Byun Y MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin Eur J Pharm Biopharm 2007 67 3 646 654 17499491
   PubMed Web of Science ®Google Scholar
• Chau Y Dang NM Tan FE Langer R Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model J Pharm Sci 2006 95 3 542 551 16419048
   PubMed Web of Science ®Google Scholar
• Chau Y Padera RF Dang NM Langer R Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models Int J Cancer 2006 118 6 1519 1526 16187287
   PubMed Web of Science ®Google Scholar
• Chau Y Tan FE Langer R Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX Bioconjug Chem 2004 15 4 931 941 15264885
   PubMed Web of Science ®Google Scholar
• Li Y Zheng X Cao Z Xu W Zhang J Gong M Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin Int J Pharm 2012 434 1–2 209 214 22688249
   PubMed Web of Science ®Google Scholar